Date: Monday, June 13, 2016
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Halls C&D
Background: Regimens with de novo everolimus (EVR) are associated with a concentration-dependent incidence of wound healing adverse events (WHAE), but mycophenolate use also is related to WHAE. The purpose of this analysis was to compare the incidence of WHAE among three different immunosuppressive regimens.
Methods:This was a sub analysis of a single center prospective randomized study in which 288 kidney transplant recipients were randomized to: antithymocyte globulin, TAC, EVR and prednisone (r-ATG/EVR, = 85); basiliximab, TAC, EVR and prednisone; (BAS/EVR, N=101) and basiliximab, TAC, mycophenolate sodium and prednisone (BAS/MPS, N= 102). Detailed clinical evaluations of surgical wound were performed in every visit, within first year of transplant. Abdominal ultrasound evaluation was performed at 30 days of transplant to capture subclinical abnormalities. No specific surgical preventive measures were implemented.
Results: No demographic difference was observed among the groups. There was no difference in number of patients with at least one WHAE (22.3 vs. 35.3 vs. 22.0 %, p=0.067) or in number of those who required surgical reintervention (11.8 vs. 10.8 vs. 10.9%, p=0.998). Total number of WHAE was higher in BAS/EVR. Subclinical findings were observed in 13%, 12% and 8% of patients respectively.
Independent risk factors for WHAE were recipient's age (OR= 1.02, p= 0.03), waist circumference (OR= 1.04, p= <0.01), andmean blood concentration of EVR at day 30 after transplantation above 4.8 ng/mL (OR= 1.73, p= 0.05). Afro-descendents recipients were less likely to experience a WHAE than Caucasian recipients (OR=1.79, p < 0.03).
Conclusion: In this analysis, the number of patients with any WHAE was comparable in patients receiving EVR or MPS.
CITATION INFORMATION: Ueno P, Tedesco H, Brigido A, Felipe C, Hannun P, Cristelli M, Aguiar W, Medina-Pestana J. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Ueno P, Tedesco H, Brigido A, Felipe C, Hannun P, Cristelli M, Aguiar W, Medina-Pestana J. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/wound-healing-complications-in-kidney-transplant-recipients-receiving-everolimus/. Accessed June 3, 2020.
« Back to 2016 American Transplant Congress